Press Releases

16 Oct

Posted at 05:00h in Press Releases

NG101 Significantly Reduced Incidence of Nausea by 40% and Frequency of Vomiting by 56% without Changing the Safety Profile of the GLP-1 Agonist WOBURN, MA, October 16, 2024 – Neurogastrx, Inc. today announced positive topline results from a new study of NG101 (metopimazine mesylate) showing...

26 Aug

Posted at 06:30h in Press Releases

Woburn, MA – August 26, 2021 – Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced today the successful completion of a $60 million Series B crossover round led by Vivo Capital. Other new investors participating in the...

04 Jan

Posted at 10:56h in Press Releases

- JIM O'MARA NAMED CHIEF EXECUTIVE OFFICER - BOSTON, Jan. 4, 2018 /PRNewswire/ -- Neurogastrx, Inc., a private biopharmaceutical company focused on discovering and developing therapies for gastrointestinal disorders affecting the enteric nervous system, today announced a transformative $45M Series A financing co-led by 5AM Ventures, OrbiMed Advisors and venBio Partners. The funds will...

Neurogastrx, Inc.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.